Ben Asani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ben Asani has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Schiefelbein
Department of Ophthalmology, Ludwig-Maximilians-University, Mathildenstraße 8, 80336 Munich, Germany
7 shared publications - Fabian Joachim Theis
Helmholtz Center Munich
6 shared publications - Jakob Siedlecki
Department of Ophthalmology, LMU University Hospital, Ludwig-Maximilians-University, 80539 Munich, Germany
6 shared publications - Siegfried Georg Priglinger
Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany
6 shared publications Amit Frishberg
Institute of Computational Biology, Helmholtz Centre Munich, Munich, Germany
4 shared publicationsSiegfried G. Priglinger
Department of Ophthalmology, University Hospital, LMU Munich, Munich, Germany
4 shared publications
Latest Publications
- Open Access
REECAP: Contrastive learning of retinal aging reveals genetic loci linking morphology to eye disease
Deep learning foundation models excel at disease prediction from medical images, yet their potential to bridge tissue morphology with the genetic architecture of disease remains underexplored. Here, we present REECAP (Representation learning for Eye Embedding Contrastive Age Phenotypes), a framework that fine-tunes the RETFound retinal foundation model using a contrastive objective guided by chronological age. Applied to 87,478 fundus images from 52,742 UK Biobank participants, REECAP aligns image representations along the aging axis, yielding multivariate ageing phenotypes for genome-wide association studies (GWAS). GWAS of REECAP embeddings identifies 178 loci, including 27 that colocalize with risk loci of age-related eye diseases, 14 of which remained undetected by conventional disease-label GWAS. By enabling conditional image synthesis, REECAP further links genetic variation to interpretable anatomical changes. Benchmarking against alternative embedding models, we show that REECAP enhances both locus discovery and disease relevance of genetic associations, suggesting that aging-informed tissue embeddings represent a powerful intermediate phenotype to discover and interpret disease loci.
Open AccessREECAP: Contrastive learning of retinal aging reveals genetic loci linking morphology to eye disease
Deep learning foundation models excel at disease prediction from medical images, yet their potential to bridge tissue morphology with the genetic architecture of disease remains underexplored. Here, we present REECAP (Representation learning for Eye Embedding Contrastive Age Phenotypes), a framework that fine-tunes the RETFound retinal foundation model using a contrastive objective guided by chronological age. Applied to 87,478 fundus images from 52,742 UK Biobank participants, REECAP aligns image representations along the aging axis, yielding multivariate ageing phenotypes for genome-wide association studies (GWAS). GWAS of REECAP embeddings identifies 178 loci, including 27 that colocalize with risk loci of age-related eye diseases, 14 of which remained undetected by conventional disease-label GWAS. By enabling conditional image synthesis, REECAP further links genetic variation to interpretable anatomical changes. Benchmarking against alternative embedding models, we show that REECAP enhances both locus discovery and disease relevance of genetic associations, suggesting that aging-informed tissue embeddings represent a powerful intermediate phenotype to discover and interpret disease loci.
- Open Access
- 13 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7197
Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results
Background: Macular edema (ME) secondary to retinal vein occlusion (RVO) is a significant cause of vision impairment. Many patients show suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, prompting the exploration of alternative treatments. Faricimab is a bispecific antibody that targets VEGF-A and angiopoietin-2. We report 9-month real-world outcomes of switching to faricimab in therapy-resistant RVO-associated ME. Methods: In this retrospective study at a single tertiary center, patients with persistent or recurrent ME despite prior treatments (ranibizumab, aflibercept, or dexamethasone implant) were switched to faricimab. All eyes received a loading phase of four monthly faricimab injections, followed by a treat-and-extend regimen individualized per response. Key outcomes included best-corrected visual acuity (BCVA, logMAR), the central subfield thickness (CST, μm), and the intraretinal fluid (IRF) status on optical coherence tomography, assessed from the baseline (month 0, mo0) through the loading phase (mo1–mo3) and at month 9 (mo9). Results: Nineteen eyes (19 patients, mean age 64.8 years) were analyzed. The median BCVA improved from 0.20 to 0.00 logMAR by month 3 (p < 0.01) and was maintained at month 9. The median CST decreased from 325 μm at the baseline to 285 μm at month 3 (p < 0.01) and remained at 285 μm at month 9. IRF was present in 100% of eyes at the baseline, 26% at month 3, and 26% at month 9 (p < 0.01 for the baseline vs. month 9). Among eyes previously on anti-VEGF therapy (n = 14), the median treatment interval increased from 45.50 days at the baseline to 56.50 days at month 9 (p = 0.01; δ = 0.86). No intraocular inflammation or other adverse events were observed in this cohort over nine months. Conclusions: In this retrospective series, switching to faricimab was associated with improvements in vision and retinal anatomy that were maintained over 9 months; injection intervals were extended in a subset of eyes. These exploratory findings warrant confirmation in larger, controlled studies to define long-term effectiveness, safety, and dosing strategies.
- 13 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7197
Open AccessExtended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results
Background: Macular edema (ME) secondary to retinal vein occlusion (RVO) is a significant cause of vision impairment. Many patients show suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, prompting the exploration of alternative treatments. Faricimab is a bispecific antibody that targets VEGF-A and angiopoietin-2. We report 9-month real-world outcomes of switching to faricimab in therapy-resistant RVO-associated ME. Methods: In this retrospective study at a single tertiary center, patients with persistent or recurrent ME despite prior treatments (ranibizumab, aflibercept, or dexamethasone implant) were switched to faricimab. All eyes received a loading phase of four monthly faricimab injections, followed by a treat-and-extend regimen individualized per response. Key outcomes included best-corrected visual acuity (BCVA, logMAR), the central subfield thickness (CST, μm), and the intraretinal fluid (IRF) status on optical coherence tomography, assessed from the baseline (month 0, mo0) through the loading phase (mo1–mo3) and at month 9 (mo9). Results: Nineteen eyes (19 patients, mean age 64.8 years) were analyzed. The median BCVA improved from 0.20 to 0.00 logMAR by month 3 (p < 0.01) and was maintained at month 9. The median CST decreased from 325 μm at the baseline to 285 μm at month 3 (p < 0.01) and remained at 285 μm at month 9. IRF was present in 100% of eyes at the baseline, 26% at month 3, and 26% at month 9 (p < 0.01 for the baseline vs. month 9). Among eyes previously on anti-VEGF therapy (n = 14), the median treatment interval increased from 45.50 days at the baseline to 56.50 days at month 9 (p = 0.01; δ = 0.86). No intraocular inflammation or other adverse events were observed in this cohort over nine months. Conclusions: In this retrospective series, switching to faricimab was associated with improvements in vision and retinal anatomy that were maintained over 9 months; injection intervals were extended in a subset of eyes. These exploratory findings warrant confirmation in larger, controlled studies to define long-term effectiveness, safety, and dosing strategies.
- Open Access
- 20 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Suprachoroidal implantation of corticosteroid slow release implants for the treatment of cystoid macular edema
In cases of an unstable iris-lens diaphragm, intravitreal corticosteroid slow-release implants (CSRI) may accidentally migrate into the anterior chamber, leading to damage to the corneal endothelium. The purpose of this study was to evaluate the efficacy and safety of a suprachoroidal application of these primarily intravitreal implants to address this issue. In this single-center, retrospective proof of principle study, we observed consecutive cases of patients receiving dexamethasone and fluocinolon acetonide implants that were administered into the suprachoroidal space in patients with CME and instability of the iris-lens diaphragm. Treatment responses of the CME on OCT, incidence of secondary intraocular pressure increases, visual acuity and surgery related complications were evaluated. In total, 16 patients were treated and mean follow up was 1.8 ± 0.97 months. The procedure was well tolerated with no severe intraoperative or postoperative side effects. Mean central retinal thickness (CRT) decreased significantly from 563.13 to 382.12 (p = 0.002). There was no incidence of steroid induced glaucoma. Mean best corrected visual acuity (BCVA) significantly improved from 1.07 logMAR to 0.65 logMAR (p = 0.01). Suprachoroidal implantation of corticosteroid slow-release implants proves to be a safe and feasible alternative for complex eyes with CME and a disruption of the anterior-posterior segment border.
- 20 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Open AccessSuprachoroidal implantation of corticosteroid slow release implants for the treatment of cystoid macular edema
In cases of an unstable iris-lens diaphragm, intravitreal corticosteroid slow-release implants (CSRI) may accidentally migrate into the anterior chamber, leading to damage to the corneal endothelium. The purpose of this study was to evaluate the efficacy and safety of a suprachoroidal application of these primarily intravitreal implants to address this issue. In this single-center, retrospective proof of principle study, we observed consecutive cases of patients receiving dexamethasone and fluocinolon acetonide implants that were administered into the suprachoroidal space in patients with CME and instability of the iris-lens diaphragm. Treatment responses of the CME on OCT, incidence of secondary intraocular pressure increases, visual acuity and surgery related complications were evaluated. In total, 16 patients were treated and mean follow up was 1.8 ± 0.97 months. The procedure was well tolerated with no severe intraoperative or postoperative side effects. Mean central retinal thickness (CRT) decreased significantly from 563.13 to 382.12 (p = 0.002). There was no incidence of steroid induced glaucoma. Mean best corrected visual acuity (BCVA) significantly improved from 1.07 logMAR to 0.65 logMAR (p = 0.01). Suprachoroidal implantation of corticosteroid slow-release implants proves to be a safe and feasible alternative for complex eyes with CME and a disruption of the anterior-posterior segment border.
- Open Access
- 3 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2454
Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes
Background/Objectives: Macular edema (ME), due to retinal vein occlusion (RVO), is a major cause of vision impairment. Many patients experience suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, necessitating alternative treatment approaches. Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2 (Ang-2), introduces a novel dual-mechanism therapy. This study evaluates the short-term real-world efficacy of switching to Faricimab in patients with treatment-resistant ME secondary to RVO. Methods: This retrospective study included patients from LMU University Hospital who were switched to Faricimab due to an inadequate response or adverse events related to prior intravitreal therapy (Ranibizumab, Aflibercept, or OzurdexTM). All patients completed a structured loading phase of four monthly injections. Key outcome measures included changes in best-corrected visual acuity (BCVA, logMAR), central subfield thickness (CST, µm), and intraretinal fluid (IRF) presence on optical coherence tomography (OCT). Changes were assessed from baseline (mo0) to three months (mo3). Results: The study included 19 eyes from 19 patients (mean age 63.0 ± 14.2 years). BCVA improved from 0.20 logMAR at baseline to 0.00 logMAR at mo3 (p < 0.01). CST decreased from 325 µm to 280 µm (p < 0.01). The proportion of eyes with IRF reduced from 100% to 32% (p < 0.01). Significant reductions in retinal volume within the 1 mm and 6 mm (both p < 0.01) circles of the ETDRS grid were observed. Conclusions: Switching to Faricimab in patients resulted in significant short-term improvements in BCVA, CST, and IRF resolution. Given the small sample size and retrospective design, these findings should be interpreted as exploratory and hypothesis-generating. Further studies are needed to evaluate long-term efficacy and optimal treatment regimens.
- 3 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2454
Open AccessSwitching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes
Background/Objectives: Macular edema (ME), due to retinal vein occlusion (RVO), is a major cause of vision impairment. Many patients experience suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, necessitating alternative treatment approaches. Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2 (Ang-2), introduces a novel dual-mechanism therapy. This study evaluates the short-term real-world efficacy of switching to Faricimab in patients with treatment-resistant ME secondary to RVO. Methods: This retrospective study included patients from LMU University Hospital who were switched to Faricimab due to an inadequate response or adverse events related to prior intravitreal therapy (Ranibizumab, Aflibercept, or OzurdexTM). All patients completed a structured loading phase of four monthly injections. Key outcome measures included changes in best-corrected visual acuity (BCVA, logMAR), central subfield thickness (CST, µm), and intraretinal fluid (IRF) presence on optical coherence tomography (OCT). Changes were assessed from baseline (mo0) to three months (mo3). Results: The study included 19 eyes from 19 patients (mean age 63.0 ± 14.2 years). BCVA improved from 0.20 logMAR at baseline to 0.00 logMAR at mo3 (p < 0.01). CST decreased from 325 µm to 280 µm (p < 0.01). The proportion of eyes with IRF reduced from 100% to 32% (p < 0.01). Significant reductions in retinal volume within the 1 mm and 6 mm (both p < 0.01) circles of the ETDRS grid were observed. Conclusions: Switching to Faricimab in patients resulted in significant short-term improvements in BCVA, CST, and IRF resolution. Given the small sample size and retrospective design, these findings should be interpreted as exploratory and hypothesis-generating. Further studies are needed to evaluate long-term efficacy and optimal treatment regimens.
- Open Access
- 17 February 2025
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 242 (06) , 674-676
Suprachoroidal Delivery of Corticosteroid Slow-Release Implants for the Treatment of Cystoid Macular Edema
N/a1 Received: 31 December 2024 Accepted after revision: 23 January 2025 Accepted Manuscript online: 17 February 2025 © . The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 17 February 2025
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 242 (06) , 674-676
Open AccessSuprachoroidal Delivery of Corticosteroid Slow-Release Implants for the Treatment of Cystoid Macular Edema
N/a1 Received: 31 December 2024 Accepted after revision: 23 January 2025 Accepted Manuscript online: 17 February 2025 © . The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 27 July 2024
- Published by Springer Nature in Eye
- Vol. 38 (16) , 3180-3186
Evaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm
Objectives: To determine real-life quantitative changes in OCT biomarkers in a large set of treatment naive patients in a real-life setting undergoing anti-VEGF therapy. For this purpose, we devised a novel deep learning based semantic segmentation algorithm providing the first benchmark results for automatic segmentation of 11 OCT features including biomarkers for neovascular age-related macular degeneration (nAMD). Methods: Training of a Deep U-net based semantic segmentation ensemble algorithm for state-of-the-art semantic segmentation performance which was used to analyze OCT features prior to, after 3 and 12 months of anti-VEGF therapy. Results: High F1 scores of almost 1.0 for neurosensory retina and subretinal fluid on a separate hold-out test set with unseen patients. The algorithm performed worse for subretinal hyperreflective material and fibrovascular PED, on par with drusenoid PED, and better in segmenting fibrosis. In the evaluation of treatment naive OCT scans, significant changes occurred for intraretinal fluid (mean: 0.03 µm3 to 0.01 µm3, p < 0.001), subretinal fluid (0.08 µm3 to 0.01 µm3, p < 0.001), subretinal hyperreflective material (0.02 µm3 to 0.01 µm3, p < 0.001), fibrovascular PED (0.12 µm3 to 0.09 µm3, p = 0.02) and central retinal thickness C0 (225.78 µm3 to 169.40 µm3). The amounts of intraretinal fluid, fibrovascular PED, and ERM were predictive of poor outcome. Conclusions: The segmentation algorithm allows efficient volumetric analysis of OCT scans. Anti-VEGF provokes most potent changes in the first 3 months while a gradual loss of RPE hints at a progressing decline of visual acuity. Additional research is required to understand how these accurate OCT predictions can be leveraged for a personalized therapy regimen.
- 27 July 2024
- Published by Springer Nature in Eye
- Vol. 38 (16) , 3180-3186
Open AccessEvaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm
Objectives: To determine real-life quantitative changes in OCT biomarkers in a large set of treatment naive patients in a real-life setting undergoing anti-VEGF therapy. For this purpose, we devised a novel deep learning based semantic segmentation algorithm providing the first benchmark results for automatic segmentation of 11 OCT features including biomarkers for neovascular age-related macular degeneration (nAMD). Methods: Training of a Deep U-net based semantic segmentation ensemble algorithm for state-of-the-art semantic segmentation performance which was used to analyze OCT features prior to, after 3 and 12 months of anti-VEGF therapy. Results: High F1 scores of almost 1.0 for neurosensory retina and subretinal fluid on a separate hold-out test set with unseen patients. The algorithm performed worse for subretinal hyperreflective material and fibrovascular PED, on par with drusenoid PED, and better in segmenting fibrosis. In the evaluation of treatment naive OCT scans, significant changes occurred for intraretinal fluid (mean: 0.03 µm3 to 0.01 µm3, p < 0.001), subretinal fluid (0.08 µm3 to 0.01 µm3, p < 0.001), subretinal hyperreflective material (0.02 µm3 to 0.01 µm3, p < 0.001), fibrovascular PED (0.12 µm3 to 0.09 µm3, p = 0.02) and central retinal thickness C0 (225.78 µm3 to 169.40 µm3). The amounts of intraretinal fluid, fibrovascular PED, and ERM were predictive of poor outcome. Conclusions: The segmentation algorithm allows efficient volumetric analysis of OCT scans. Anti-VEGF provokes most potent changes in the first 3 months while a gradual loss of RPE hints at a progressing decline of visual acuity. Additional research is required to understand how these accurate OCT predictions can be leveraged for a personalized therapy regimen.
- Open Access
- 27 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Reconstructing disease dynamics for mechanistic insights and clinical benefit
Diseases change over time, both phenotypically and in their underlying molecular processes. Though understanding disease progression dynamics is critical for diagnostics and treatment, capturing these dynamics is difficult due to their complexity and the high heterogeneity in disease development between individuals. We present TimeAx, an algorithm which builds a comparative framework for capturing disease dynamics using high-dimensional, short time-series data. We demonstrate the utility of TimeAx by studying disease progression dynamics for multiple diseases and data types. Notably, for urothelial bladder cancer tumorigenesis, we identify a stromal pro-invasion point on the disease progression axis, characterized by massive immune cell infiltration to the tumor microenvironment and increased mortality. Moreover, the continuous TimeAx model differentiates between early and late tumors within the same tumor subtype, uncovering molecular transitions and potential targetable pathways. Overall, we present a powerful approach for studying disease progression dynamics—providing improved molecular interpretability and clinical benefits for patient stratification and outcome prediction.
- 27 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Open AccessReconstructing disease dynamics for mechanistic insights and clinical benefit
Diseases change over time, both phenotypically and in their underlying molecular processes. Though understanding disease progression dynamics is critical for diagnostics and treatment, capturing these dynamics is difficult due to their complexity and the high heterogeneity in disease development between individuals. We present TimeAx, an algorithm which builds a comparative framework for capturing disease dynamics using high-dimensional, short time-series data. We demonstrate the utility of TimeAx by studying disease progression dynamics for multiple diseases and data types. Notably, for urothelial bladder cancer tumorigenesis, we identify a stromal pro-invasion point on the disease progression axis, characterized by massive immune cell infiltration to the tumor microenvironment and increased mortality. Moreover, the continuous TimeAx model differentiates between early and late tumors within the same tumor subtype, uncovering molecular transitions and potential targetable pathways. Overall, we present a powerful approach for studying disease progression dynamics—providing improved molecular interpretability and clinical benefits for patient stratification and outcome prediction.
- Open Access
Deep Learning based retinal layer segmentation in optical coherence tomography scans of patients with inherited retinal diseases
Background: On optical coherence tomography (OCT) scans of patients with inherited retinal diseases (IRDs), the outer nuclear layer (ONL) thickness measurement has been well established as a surrogate marker for photoreceptor preservation. Current automatic segmentation tools fail in OCT segmentation in IRDs, and manual segmentation is time consuming. Methods and Material: Patients with IRD and the availability of an OCT scan were screened for the present study. Additionally, OCT scans of patients without retinal disease were included, to provide training data for the artificial intelligence (AI). We trained a U-net based model on healthy patients and applied a domain adaption technique to IRD patients’ scans. Results: We established an AI-based image segmentation algorithm that reliably segments the ONL in OCT scans of IRD patients. In a test dataset, the dice-score of the algorithm was 98.7% . Furthermore, we generated thickness maps of the full retinal thickness and the ONL layer for each patient. Conclusion: Accurate segmentation of anatomical layers on OCT scans plays a crucial role for predictive models linking retinal structure to visual function. The here-presented OCT image segmentation algorithm could provide the basis for further studies on IRDs.
Open AccessDeep Learning based retinal layer segmentation in optical coherence tomography scans of patients with inherited retinal diseases
Background: On optical coherence tomography (OCT) scans of patients with inherited retinal diseases (IRDs), the outer nuclear layer (ONL) thickness measurement has been well established as a surrogate marker for photoreceptor preservation. Current automatic segmentation tools fail in OCT segmentation in IRDs, and manual segmentation is time consuming. Methods and Material: Patients with IRD and the availability of an OCT scan were screened for the present study. Additionally, OCT scans of patients without retinal disease were included, to provide training data for the artificial intelligence (AI). We trained a U-net based model on healthy patients and applied a domain adaption technique to IRD patients’ scans. Results: We established an AI-based image segmentation algorithm that reliably segments the ONL in OCT scans of IRD patients. In a test dataset, the dice-score of the algorithm was 98.7% . Furthermore, we generated thickness maps of the full retinal thickness and the ONL layer for each patient. Conclusion: Accurate segmentation of anatomical layers on OCT scans plays a crucial role for predictive models linking retinal structure to visual function. The here-presented OCT image segmentation algorithm could provide the basis for further studies on IRDs.
- Open Access
Evaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm
Purpose: To determine real life quantitative changes in OCT biomarkers in a large set of treatment naive patients undergoing anti-VEGF therapy. For this purpose, we devised a novel deep learning based semantic segmentation algorithm providing, to the best of our knowledge, the first benchmark results for automatic segmentation of 11 OCT features including biomarkers that are in line with the latest consensus nomenclature of the AAO for age-related macular degeneration (AMD). Design: Retrospective study. Participants: Segmentation algorithm training set of 458 volume scans as well as single scans from 363 treatment naive patients for the analysis. Methods: Training of a Deep U-net based semantic segmentation ensemble algorithm leveraging multiple deep convolutional neural networks for state of the art semantic segmentation performance as well as analyzing OCT features prior to, after 3 and 12 months of anti-VEGF therapy. Main outcome measures: F1 score for the segmentation efficiency and the quantified volumes of 11 OCT features. Results: The segmentation algorithm achieved high F1 scores of almost 1.0 for neurosensory retina and subretinal fluid on a separate hold out test set with unseen patients. The algorithm performed worse for subretinal hyperreflective material and fibrovascular PED, on par with drusenoid PED and better in segmenting fibrosis. In the evaluation of treatment naive OCT scans, significant changes occurred for intraretinal fluid (mean: 0.03µm 3 to 0.01µm 3 , p3 to 0.01µm 3 , p3 to 0.01µm 3 , p3 to 0.09µm 3 , p=0.02) and central retinal thickness C0 (225.78µm 3 to 169.40µm 3 ).The amounts of intraretinal fluid, fibrovascular PED and ERM were predictive of poor outcome. Conclusions: The segmentation algorithm allows efficient volumetric analysis of OCT scans. Anti-VEGF therapy provokes most potent changes in the first 3 months and afterwards only acts as a stabilizing agent. Furthermore, a gradual loss of RPE hints at a progressing decline of visual acuity even beyond month 12. Additional research is required to understand how these accurate OCT predictions can be leveraged for a personalized therapy regimen. Précis: Novel high performance segmentation algorithm shows most volumetric changes under anti-VEGF therapy in oct biomarkers occur in the first 3 months. Afterwards the injections seem only to serve as a stabilizing agent.
Open AccessEvaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm
Purpose: To determine real life quantitative changes in OCT biomarkers in a large set of treatment naive patients undergoing anti-VEGF therapy. For this purpose, we devised a novel deep learning based semantic segmentation algorithm providing, to the best of our knowledge, the first benchmark results for automatic segmentation of 11 OCT features including biomarkers that are in line with the latest consensus nomenclature of the AAO for age-related macular degeneration (AMD). Design: Retrospective study. Participants: Segmentation algorithm training set of 458 volume scans as well as single scans from 363 treatment naive patients for the analysis. Methods: Training of a Deep U-net based semantic segmentation ensemble algorithm leveraging multiple deep convolutional neural networks for state of the art semantic segmentation performance as well as analyzing OCT features prior to, after 3 and 12 months of anti-VEGF therapy. Main outcome measures: F1 score for the segmentation efficiency and the quantified volumes of 11 OCT features. Results: The segmentation algorithm achieved high F1 scores of almost 1.0 for neurosensory retina and subretinal fluid on a separate hold out test set with unseen patients. The algorithm performed worse for subretinal hyperreflective material and fibrovascular PED, on par with drusenoid PED and better in segmenting fibrosis. In the evaluation of treatment naive OCT scans, significant changes occurred for intraretinal fluid (mean: 0.03µm 3 to 0.01µm 3 , p3 to 0.01µm 3 , p3 to 0.01µm 3 , p3 to 0.09µm 3 , p=0.02) and central retinal thickness C0 (225.78µm 3 to 169.40µm 3 ).The amounts of intraretinal fluid, fibrovascular PED and ERM were predictive of poor outcome. Conclusions: The segmentation algorithm allows efficient volumetric analysis of OCT scans. Anti-VEGF therapy provokes most potent changes in the first 3 months and afterwards only acts as a stabilizing agent. Furthermore, a gradual loss of RPE hints at a progressing decline of visual acuity even beyond month 12. Additional research is required to understand how these accurate OCT predictions can be leveraged for a personalized therapy regimen. Précis: Novel high performance segmentation algorithm shows most volumetric changes under anti-VEGF therapy in oct biomarkers occur in the first 3 months. Afterwards the injections seem only to serve as a stabilizing agent.
- Open Access
- 7 April 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (9) , 807-813
Progression of Pachychoroid Neovasculopathy into Aneurysmal Type 1 Choroidal Neovascularization or Polypoidal Choroidal Vasculopathy
- 7 April 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (9) , 807-813
Open AccessProgression of Pachychoroid Neovasculopathy into Aneurysmal Type 1 Choroidal Neovascularization or Polypoidal Choroidal Vasculopathy